Patients may have a preference about what preparation they take, whether it's a tablet or injection, how frequently they need to take it, and at what times of day. 

There are a number of recommendations relating to the holistic management of patients starting insulin-based treatments in the NICE guideline and this covers the content of structured education programmes, as well as a choice of insulin and monitoring arrangements. 

GLP-1 mimetics are injectables available for use at second intensification as part of triple therapy. They are recommended for patients where: 

• BMI is 35kg/m2 or higher, or 
• BMI is lower than 35kg/m2 and insulin therapy would have significant occupational implications, or
• Weight loss would benefit other significant obesity-related comorbidities. 

If a patient drives, they should speak to the pharmacist or GP about whether they need to inform the DVLA of their condition.

The need for self-monitoring of blood glucose may be a key consideration for many patients. Some people might like the idea of knowing that their treatment is working, but others may have difficulty undertaking the tests and responding appropriately to results. The NICE guidelines for type 2 diabetes are quite clear that self-monitoring of blood glucose should be the exception, rather than the rule. Use of insulin and oral medicines that can cause hypoglycaemia are the main justifiable reasons for including self-monitoring in a treatment plan. 

No medicines are without side effects, and these may affect some people more frequently and to a greater extent than others. For example, some patients are willing to tolerate the increased urinary frequency associated with SGLT-2 inhibitors, but a patient with mobility problems may find this inconvenient.